Canon U.S.A. (Lake Success, New York) said it showcased the latest addition to its family of portable digital radiology (DR) systems — the Canon CXDI-50C — at the Society for Computer Applications in Radiology Show held last week in Austin, Texas. The CXDI-50C lightweight DR system provides filmless image capture for a range of radiographic applications, including trauma and bedside exams. The large imaging area and portable design allow the system to be especially useful with patients who have limited mobility and for capturing images at angles that are difficult to set with fixed devices, the company said. Featuring Canon LANMIT (Large Area New-MIS Sensor and TFT) detector technology, the system delivers high-quality diagnostic images efficiently with minimal X-ray exposure to patients. The portable DR system consists of a Canon Amorphous Silicon Flat Panel Detector and a Cesium Iodide scintillator, and has network capability.

Cardiogenesis (Foothill Ranch, California), a manufacturer of surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures, reported that investigators with growing experience using advanced minimally invasive TMR surgical tools in the PEARL (Port Enabled Angina Relief with Laser) trial, have begun presenting their findings at prominent scientific meetings and in clinical publications. The PEARL trial is a nationwide investigation of new devices enabling the application of transmyocardial revascularization through minimally invasive port access. These port access procedures allow surgeons to treat patients who suffer from chronic severe angina using novel robotic and thoracoscopic techniques. Findings on the Cardiogenesis PEARL 5.0 device for TMR was presented last week at the Advanced Cardiac Techniques in Surgery meeting in New York, in which the investigator found “that these techniques can provide patients the substantial angina relief of TMR while significantly speeding patient recovery times.”

CryoPen (Houston), a manufacturer of cryosurgery instruments, reported the launch of the CryoPen Cryosurgical System. The hand-held unit is portable and requires no dangerous gases or liquids for operation. The device features optimal, consistent freeze temperatures for simple, safe and effective lesion removal.

NeoPharm (Waukegan, Illinois) reported that the use of a new software-based catheter planning and positioning system developed by BrainLAB (Munich, Germany) may optimize the efficacy and safety of tumor targeting therapies delivered via Convection Enhanced Delivery (CED), specifically cintredekin besudotox (IL13-PE38QQRR), an investigational treatment being studied for the treatment of patients with first recurrent glioblastoma multiforme. The company said investigators evaluated the clinical usefulness of a novel simulation algorithm using MR diffusion tensor imaging to predict the distribution of a drug administered via CED. Overall, investigators found that the new software simulation technique provides valuable patient-specific information including volume, location, and geometry of potential drug distribution. This information can be effectively used to assist in optimizing planning and subsequent positioning of drug delivery catheters for CED. The new technology is applied to neoplastic and other CNS pathologies.

Non-Invasive Monitoring Systems (North Bay Village, Florida) said it recently received notice of allowance for a third U.S. patent on its flagship product, the AT-101, a non-invasive device that applies whole -body vibration by moving a person lying on a platform repetitively head to foot about 140 times per minute. The patent includes 151 claims pertaining to the scientific basis for the action of the device and its current and future medical applications, including its future use of whole body vibration in combination with drugs such as statins, L-Arginine and beta-blockers for pain relief.

Ortec International (New York), which is developing products applicable to regenerative medicine and stem cell therapy, reported completing patient enrollment of a trial designed to confirm the superiority of cryopreserved OrCel in the healing of difficult to heal venous leg ulcers in comparison to the standard of care therapy. Upon completion of the 12-week treatment phase for the last patient enrolled, the data of this trial will be analyzed. The primary endpoint efficacy data of the 61 patients enrolled in this trial are intended to be integrated with results of 61 patients from the company's pivotal trial. The combined results will be analyzed and reported using a Bayesian statistical approach. The trial is being conducted at ten clinical sites throughout the U.S.

Petersen Medical (Salt Lake City), a provider of home medical equipment and dedicated in-home professional service, said that the company will be the first provider of the Inogen One system for the state of Utah. The new lightweight product, manufactured by Inogen (Santa Barbara, California), is a tank-free portable oxygen concentrator system, designed to help patients with limiting respiratory conditions breathe easier while enhancing their mobility and quality of life. The product features a Satellite Conserver, which extends the patient's range by allowing oxygen to be delivered up to 100 feet from the device.

Sorin Group (Milan, Italy), Europe's largest medical technology company specialized in the treatment of cardiovascular diseases and leader in cardiac surgery, presented at the 86th AATS Congress in Philadelphia, the latest clinical results on Freedom Solo valve (available in Europe) and Memo 3D Annuloplasty Ring (CE and FDA pending) during a satellite symposium. Freedom Solo is a pericardial valve, easy to implant in supra- annular positioning, designed to mimic the native aortic valve and ensuring excellent haemo-dynamic performance. Memo 3D's cell-structure design is capable of mimicking the physiological three-dimensional motility of the native mitral annulus and accommodating the anatomical saddle shape. It features shape memory and super-elastic alloy core aimed at restoring the native shape and function, and Sorin Group's Carbofilm coating for enhanced haemo- and bio-compatibility.

St. Jude Medical (St. Paul, Minnesota) reported FDA approval, receipt of CE mark clearance and market launch of the QuickSite XL bipolar, left-heart lead to treat heart failure patients. The QuickSite XL lead is used in cardiac resynchronization therapy (CRT) procedures for heart failure patients with average to large size veins. The lead's heightened S-shape is designed to provide stability and allow physicians to successfully position it in bigger veins. The QuickSite XL lead complements two previously approved products in the QuickSite lead family. Studies have shown that QuickSite leads maneuver well through difficult passageways in the heart and remain stable at sites selected by physicians for optimal care, resulting in a high implant success rate and low dislodgement rate. The QuickSite XL bipolar lead is designed for use with St. Jude Medical's Epic HF CRT-D (CRT defibrillator), the Atlas+ HF CRT-D, and the Frontier II CRT-P, the world's smallest and longest-lasting CRT pacemaker, to treat heart failure.

Synova Healthcare (Media, Pennsylvania), a subsidiary of Synova Healthcare Group, reported that the Fem-V Vaginal Infection Test will be introduced at the 54th annual clinical meeting of the American College of Obstetricians and Gynecologists, which begins Saturday in Washington. Fem-V is an over-the-counter, non-invasive diagnostic test developed to assist women in the diagnosis of vaginal infections, directing them toward the appropriate treatment for the condition. For the millions of American women who experience vaginal infections annually, this novel, easy-to-use, at-home test found within a unique pantiliner design, will help determine if an over-the-counter treatment may be considered for symptoms, or if the user should seek treatment from a healthcare professional.